448 related articles for article (PubMed ID: 20501833)
21. LY2603618, a selective CHK1 inhibitor, enhances the anti-tumor effect of gemcitabine in xenograft tumor models.
Barnard D; Diaz HB; Burke T; Donoho G; Beckmann R; Jones B; Barda D; King C; Marshall M
Invest New Drugs; 2016 Feb; 34(1):49-60. PubMed ID: 26612134
[TBL] [Abstract][Full Text] [Related]
22. A kinome screen identifies checkpoint kinase 1 (CHK1) as a sensitizer for RRM1-dependent gemcitabine efficacy.
Zhou J; Chen Z; Malysa A; Li X; Oliveira P; Zhang Y; Bepler G
PLoS One; 2013; 8(3):e58091. PubMed ID: 23483975
[TBL] [Abstract][Full Text] [Related]
23. Chk1 inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers.
Bryant C; Rawlinson R; Massey AJ
BMC Cancer; 2014 Aug; 14():570. PubMed ID: 25104095
[TBL] [Abstract][Full Text] [Related]
24. Potentiation of the novel topoisomerase I inhibitor indenoisoquinoline LMP-400 by the cell checkpoint and Chk1-Chk2 inhibitor AZD7762.
Aris SM; Pommier Y
Cancer Res; 2012 Feb; 72(4):979-89. PubMed ID: 22189968
[TBL] [Abstract][Full Text] [Related]
25. Discovery of checkpoint kinase inhibitor (S)-5-(3-fluorophenyl)-N-(piperidin-3-yl)-3-ureidothiophene-2-carboxamide (AZD7762) by structure-based design and optimization of thiophenecarboxamide ureas.
Oza V; Ashwell S; Almeida L; Brassil P; Breed J; Deng C; Gero T; Grondine M; Horn C; Ioannidis S; Liu D; Lyne P; Newcombe N; Pass M; Read J; Ready S; Rowsell S; Su M; Toader D; Vasbinder M; Yu D; Yu Y; Xue Y; Zabludoff S; Janetka J
J Med Chem; 2012 Jun; 55(11):5130-42. PubMed ID: 22551018
[TBL] [Abstract][Full Text] [Related]
26. The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy.
Prevo R; Fokas E; Reaper PM; Charlton PA; Pollard JR; McKenna WG; Muschel RJ; Brunner TB
Cancer Biol Ther; 2012 Sep; 13(11):1072-81. PubMed ID: 22825331
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of checkpoint kinase 1 sensitizes lung cancer brain metastases to radiotherapy.
Yang H; Yoon SJ; Jin J; Choi SH; Seol HJ; Lee JI; Nam DH; Yoo HY
Biochem Biophys Res Commun; 2011 Mar; 406(1):53-8. PubMed ID: 21291864
[TBL] [Abstract][Full Text] [Related]
28. The preclinical pharmacology and therapeutic activity of the novel CHK1 inhibitor SAR-020106.
Walton MI; Eve PD; Hayes A; Valenti M; De Haven Brandon A; Box G; Boxall KJ; Aherne GW; Eccles SA; Raynaud FI; Williams DH; Reader JC; Collins I; Garrett MD
Mol Cancer Ther; 2010 Jan; 9(1):89-100. PubMed ID: 20053762
[TBL] [Abstract][Full Text] [Related]
29. Chk1 and Chk2 are differentially involved in homologous recombination repair and cell cycle arrest in response to DNA double-strand breaks induced by camptothecins.
Huang M; Miao ZH; Zhu H; Cai YJ; Lu W; Ding J
Mol Cancer Ther; 2008 Jun; 7(6):1440-9. PubMed ID: 18566216
[TBL] [Abstract][Full Text] [Related]
30. Targeting radioresistant breast cancer cells by single agent CHK1 inhibitor via enhancing replication stress.
Zhang Y; Lai J; Du Z; Gao J; Yang S; Gorityala S; Xiong X; Deng O; Ma Z; Yan C; Susana G; Xu Y; Zhang J
Oncotarget; 2016 Jun; 7(23):34688-702. PubMed ID: 27167194
[TBL] [Abstract][Full Text] [Related]
31. ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status.
Huntoon CJ; Flatten KS; Wahner Hendrickson AE; Huehls AM; Sutor SL; Kaufmann SH; Karnitz LM
Cancer Res; 2013 Jun; 73(12):3683-91. PubMed ID: 23548269
[TBL] [Abstract][Full Text] [Related]
32. Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models.
Ma CX; Cai S; Li S; Ryan CE; Guo Z; Schaiff WT; Lin L; Hoog J; Goiffon RJ; Prat A; Aft RL; Ellis MJ; Piwnica-Worms H
J Clin Invest; 2012 Apr; 122(4):1541-52. PubMed ID: 22446188
[TBL] [Abstract][Full Text] [Related]
33. The checkpoint kinase inhibitor AZD7762 potentiates chemotherapy-induced apoptosis of p53-mutated multiple myeloma cells.
Landau HJ; McNeely SC; Nair JS; Comenzo RL; Asai T; Friedman H; Jhanwar SC; Nimer SD; Schwartz GK
Mol Cancer Ther; 2012 Aug; 11(8):1781-8. PubMed ID: 22653969
[TBL] [Abstract][Full Text] [Related]
34. Phase I, dose-escalation study of AZD7762 alone and in combination with gemcitabine in Japanese patients with advanced solid tumours.
Seto T; Esaki T; Hirai F; Arita S; Nosaki K; Makiyama A; Kometani T; Fujimoto C; Hamatake M; Takeoka H; Agbo F; Shi X
Cancer Chemother Pharmacol; 2013 Sep; 72(3):619-27. PubMed ID: 23892959
[TBL] [Abstract][Full Text] [Related]
35. Combined CDKN1A/TP53 mutation in bladder cancer is a therapeutic target.
Liu Y; Kwiatkowski DJ
Mol Cancer Ther; 2015 Jan; 14(1):174-82. PubMed ID: 25349305
[TBL] [Abstract][Full Text] [Related]
36. Enhancement of hypoxia-activated prodrug TH-302 anti-tumor activity by Chk1 inhibition.
Meng F; Bhupathi D; Sun JD; Liu Q; Ahluwalia D; Wang Y; Matteucci MD; Hart CP
BMC Cancer; 2015 May; 15():422. PubMed ID: 25994202
[TBL] [Abstract][Full Text] [Related]
37. Combined inhibition of Wee1 and PARP1/2 for radiosensitization in pancreatic cancer.
Karnak D; Engelke CG; Parsels LA; Kausar T; Wei D; Robertson JR; Marsh KB; Davis MA; Zhao L; Maybaum J; Lawrence TS; Morgan MA
Clin Cancer Res; 2014 Oct; 20(19):5085-96. PubMed ID: 25117293
[TBL] [Abstract][Full Text] [Related]
38. Acetyl-macrocalin B suppresses tumor growth in esophageal squamous cell carcinoma and exhibits synergistic anti-cancer effects with the Chk1/2 inhibitor AZD7762.
Wang JN; Che Y; Yuan ZY; Lu ZL; Li Y; Zhang ZR; Li N; Li RD; Wan J; Sun HD; Sun N; Puno PT; He J
Toxicol Appl Pharmacol; 2019 Feb; 365():71-83. PubMed ID: 30633885
[TBL] [Abstract][Full Text] [Related]
39. Role of checkpoint kinase 1 in preventing premature mitosis in response to gemcitabine.
Morgan MA; Parsels LA; Parsels JD; Mesiwala AK; Maybaum J; Lawrence TS
Cancer Res; 2005 Aug; 65(15):6835-42. PubMed ID: 16061666
[TBL] [Abstract][Full Text] [Related]
40. Small-molecule survivin inhibitor YM155 enhances radiosensitization in esophageal squamous cell carcinoma by the abrogation of G2 checkpoint and suppression of homologous recombination repair.
Qin Q; Cheng H; Lu J; Zhan L; Zheng J; Cai J; Yang X; Xu L; Zhu H; Zhang C; Liu J; Ma J; Zhang X; Dai S; Sun X
J Hematol Oncol; 2014 Aug; 7():62. PubMed ID: 25139395
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]